{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T14:37:57Z","timestamp":1793025477043,"version":"4.5.0"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018693","name":"HORIZON EUROPE Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental and Molecular Pathology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.yexmp.2026.105085","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T07:59:47Z","timestamp":1792223987000},"page":"105085","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["MicroRNAs in prostate cancer radioresistance: mechanisms, target-based network analysis and translational opportunities"],"prefix":"10.1016","volume":"148","author":[{"given":"I.","family":"Ferreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.L.","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.yexmp.2026.105085_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2007.09.022","article-title":"NF-kappa B-mediated adaptive resistance to ionizing radiation","volume":"44","author":"Ahmed","year":"2008","journal-title":"Free Radic. Biol. Med."},{"issue":"3","key":"10.1016\/j.yexmp.2026.105085_bb0010","first-page":"133","article-title":"Molecularly targeted radiosensitization chances towards gene aberration-due organ confined\/regionally advanced prostate cancer radioresistance","volume":"36","author":"Alberti","year":"2015","journal-title":"Il G. Chir."},{"key":"10.1016\/j.yexmp.2026.105085_bb0015","article-title":"The use of androgen deprivation therapy in combination with radiation for localized prostate cancer","volume":"2-2022","author":"Anderson","year":"2022","journal-title":"Front. Urol."},{"issue":"4","key":"10.1016\/j.yexmp.2026.105085_bb0020","doi-asserted-by":"crossref","first-page":"343","DOI":"10.6004\/jnccn.2021.7061","article-title":"Outcomes of patients with unfavorable intermediate-risk prostate cancer treated with external-beam radiotherapy versus brachytherapy alone","volume":"20","author":"Andruska","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"issue":"4","key":"10.1016\/j.yexmp.2026.105085_bb0025","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/bjc.2011.595","article-title":"Changes in circulating microRNA levels associated with prostate cancer","volume":"106","author":"Bryant","year":"2012","journal-title":"Br. J. Cancer"},{"issue":"17","key":"10.1016\/j.yexmp.2026.105085_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174257","article-title":"A review on the current treatment paradigm in high-risk prostate cancer","volume":"13","author":"Burgess","year":"2021","journal-title":"Cancers"},{"issue":"18","key":"10.1016\/j.yexmp.2026.105085_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810211","article-title":"Biological mechanisms to reduce radioresistance and increase the efficacy of radiotherapy: state of the art","volume":"23","author":"Busato","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.yexmp.2026.105085_bb0040","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jcp.25048","article-title":"Mechanisms and consequences of double-strand DNA break formation in chromatin","volume":"231","author":"Cannan","year":"2016","journal-title":"J. Cell. Physiol."},{"issue":"1","key":"10.1016\/j.yexmp.2026.105085_bb0045","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-023-01696-4","article-title":"Secreted miR-210-3p, miR-183-5p and miR-96-5p reduce sensitivity to docetaxel in prostate cancer cells","volume":"9","author":"Canovai","year":"2023","journal-title":"Cell Death Discov."},{"issue":"2","key":"10.1016\/j.yexmp.2026.105085_bb0050","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bbrc.2019.05.120","article-title":"Exosome-derived miR-27a produced by PSC-27\u202fcells contributes to prostate cancer chemoresistance through p53","volume":"515","author":"Cao","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1\u20132","key":"10.1016\/j.yexmp.2026.105085_bb0055","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1615\/CritRevOncog.2018025946","article-title":"Profiles of radioresistance mechanisms in prostate cancer","volume":"23","author":"Chaiswing","year":"2018","journal-title":"Crit. Rev. Oncog."},{"issue":"10","key":"10.1016\/j.yexmp.2026.105085_bb0060","doi-asserted-by":"crossref","first-page":"e1437","DOI":"10.1038\/cddis.2014.415","article-title":"PI3K\/Akt\/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways","volume":"5","author":"Chang","year":"2014","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/j.yexmp.2026.105085_bb0065","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.critrevonc.2015.07.005","article-title":"Targeting PI3K\/Akt\/mTOR signaling pathway in the treatment of prostate cancer radioresistance","volume":"96","author":"Chang","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"7","key":"10.1016\/j.yexmp.2026.105085_bb0070","doi-asserted-by":"crossref","first-page":"833","DOI":"10.7150\/ijbs.10564","article-title":"ROS\/Autophagy\/Nrf2 pathway mediated low-dose radiation induced radio-resistance in human lung adenocarcinoma A549 cell","volume":"11","author":"Chen","year":"2015","journal-title":"Int. J. Biol. Sci."},{"issue":"7","key":"10.1016\/j.yexmp.2026.105085_bb0075","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-022-05084-1","article-title":"Second generation androgen receptor antagonists and challenges in prostate cancer treatment","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.yexmp.2026.105085_bb0080","first-page":"153","article-title":"Circular RNA LPAR3 targets JPT1 via microRNA-513b-5p to facilitate glycolytic activation but repress prostate cancer radiosensitivity","volume":"70","author":"Chen","year":"2023","journal-title":"Acta Biochim. Pol."},{"issue":"3","key":"10.1016\/j.yexmp.2026.105085_bb0085","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.1439","article-title":"Time trends and variation in the use of active surveillance for management of low-risk prostate cancer in the US","volume":"6","author":"Cooperberg","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.yexmp.2026.105085_bb0090","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer \u2013 2024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.yexmp.2026.105085_bb0095","doi-asserted-by":"crossref","first-page":"308","DOI":"10.21037\/tau.2017.12.37","article-title":"Image-guided radiotherapy for prostate cancer","volume":"7","author":"Dang","year":"2018","journal-title":"Transl. Androl. Urol."},{"key":"10.1016\/j.yexmp.2026.105085_bb0100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phro.2018.06.005","article-title":"Biochemical recurrence prediction after radiotherapy for prostate cancer with T2w magnetic resonance imaging radiomic features","volume":"7","author":"Dinis Fernandes","year":"2018","journal-title":"Phys. Imaging Radiat. Oncol."},{"key":"10.1016\/j.yexmp.2026.105085_bb0110","doi-asserted-by":"crossref","unstructured":"El Bezawy, R., Tinelli, S., Tortoreto, M., Doldi, V., Zuco, V., Folini, M., Stucchi, C., Rancati, T., Valdagni, R., Gandellini, P., & Zaffaroni, N. MiR-205 enhances radiation sensitivity of prostate cancer cells by impairing DNA damage repair through PKC\u03b5 and ZEB1 inhibition. J. Exp. Clin. Cancer Res. 38(1):51. doi:https:\/\/doi.org\/10.1186\/s13046-019-1060-z.","DOI":"10.1186\/s13046-019-1060-z"},{"key":"10.1016\/j.yexmp.2026.105085_bb0105","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.canlet.2017.02.033","article-title":"MiR-875-5p counteracts epithelial-to-mesenchymal transition and enhances radiation response in prostate cancer through repression of the EGFR-ZEB1 axis","volume":"395","author":"El Bezawy","year":"2017","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.yexmp.2026.105085_bb0115","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/ijc.35278","article-title":"The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide","volume":"156","author":"Filho","year":"2025","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.yexmp.2026.105085_bb0120","doi-asserted-by":"crossref","first-page":"297","DOI":"10.21037\/tau.2017.12.16","article-title":"Intensity-modulated radiotherapy for prostate cancer","volume":"7","author":"Fischer-Valuck","year":"2018","journal-title":"Transl. Androl. Urol."},{"key":"10.1016\/j.yexmp.2026.105085_bb0125","doi-asserted-by":"crossref","DOI":"10.1186\/1476-4598-9-12","article-title":"MiR-21: an oncomir on strike in prostate cancer","volume":"9","author":"Folini","year":"2010","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.yexmp.2026.105085_bb0130","article-title":"Radiation resistance: a matter of transcription factors","volume":"11-2021","author":"Galeaz","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.yexmp.2026.105085_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2020.144995","article-title":"Role of microRNAs in the development, prognosis and therapeutic response of patients with prostate cancer","volume":"759","author":"Ghafouri-Fard","year":"2020","journal-title":"Gene"},{"issue":"14","key":"10.1016\/j.yexmp.2026.105085_bb0140","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1158\/0008-5472.CAN-12-4640","article-title":"A survivin-associated adaptive response in radiation therapy","volume":"73","author":"Grdina","year":"2013","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.yexmp.2026.105085_bb0145","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/cam4.664","article-title":"Hypoxia-responsive miR-124 and miR-144 reduce hypoxia-induced autophagy and enhance radiosensitivity of prostate cancer cells via suppressing PIM1","volume":"5","author":"Gu","year":"2016","journal-title":"Cancer Med."},{"key":"10.1016\/j.yexmp.2026.105085_bb0150","article-title":"The role of exosomal microRNA in cancer drug resistance","volume":"10","author":"Guo","year":"2020","journal-title":"Front. Oncol."},{"issue":"S1","key":"10.1016\/j.yexmp.2026.105085_bb0155","doi-asserted-by":"crossref","first-page":"i99","DOI":"10.1093\/jrr\/rrw012","article-title":"Hypoxia-inducible factor 1\u2013mediated characteristic features of cancer cells for tumor radioresistance","volume":"57","author":"Harada","year":"2016","journal-title":"J. Radiat. Res."},{"issue":"1","key":"10.1016\/j.yexmp.2026.105085_bb0160","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms7053","article-title":"MnSOD upregulation sustains the Warburg effect via mitochondrial ROS and AMPK-dependent signalling in cancer","volume":"6","author":"Hart","year":"2015","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.yexmp.2026.105085_bb0165","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/1878-0261.12328","article-title":"MiRNA-106a and prostate cancer radioresistance: a novel role for LITAF in ATM regulation","volume":"12","author":"Hoey","year":"2018","journal-title":"Mol. Oncol."},{"issue":"10","key":"10.1016\/j.yexmp.2026.105085_bb0170","article-title":"HIF-1 signaling: a key orchestrator of cancer radioresistance","volume":"1","author":"Huang","year":"2020","journal-title":"Radiat. Med. Prot."},{"issue":"23","key":"10.1016\/j.yexmp.2026.105085_bb0175","doi-asserted-by":"crossref","first-page":"6972","DOI":"10.1158\/0008-5472.CAN-13-1657","article-title":"MiRNA-95 mediates radioresistance in tumors by targeting the sphingolipid phosphatase SGPP1","volume":"73","author":"Huang","year":"2013","journal-title":"Cancer Res."},{"issue":"26","key":"10.1016\/j.yexmp.2026.105085_bb0180","doi-asserted-by":"crossref","first-page":"22439","DOI":"10.18632\/oncotarget.4210","article-title":"MiR-620 promotes tumor radioresistance by targeting 15-hydroxyprostaglandin dehydrogenase (HPGD)","volume":"6","author":"Huang","year":"2015","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.yexmp.2026.105085_bb0185","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1261\/rna.055301.115","article-title":"Guidelines for the functional annotation of microRNAs using the Gene Ontology","volume":"22","author":"Huntley","year":"2016","journal-title":"RNA"},{"issue":"3","key":"10.1016\/j.yexmp.2026.105085_bb0190","doi-asserted-by":"crossref","first-page":"481","DOI":"10.20517\/cdr.2023.17","article-title":"The multifaceted role of extracellular vesicles in prostate cancer-a review","volume":"6","author":"Jain","year":"2023","journal-title":"Cancer Drug Resist."},{"issue":"10437","key":"10.1016\/j.yexmp.2026.105085_bb0195","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.yexmp.2026.105085_bb0200","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s10555-020-09883-w","article-title":"FOXO transcription factor family in cancer and metastasis","volume":"39","author":"Jiramongkol","year":"2020","journal-title":"Cancer Metastasis Rev."},{"issue":"7","key":"10.1016\/j.yexmp.2026.105085_bb0205","article-title":"LHRH antagonists vs LHRH agonists: which is more beneficial in prostate cancer therapy?","volume":"23","author":"Keizman","year":"2009","journal-title":"Oncology"},{"issue":"12","key":"10.1016\/j.yexmp.2026.105085_bb0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0262017","article-title":"Evaluation of micro-RNA in extracellular vesicles from blood of patients with prostate cancer","volume":"16","author":"Kim","year":"2021","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.yexmp.2026.105085_bb0220","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/s12276-022-00898-7","article-title":"Dissecting exosome inhibitors: therapeutic insights into small-molecule chemicals against cancer","volume":"54","author":"Kim","year":"2022","journal-title":"Exp. Mol. Med."},{"issue":"1","key":"10.1016\/j.yexmp.2026.105085_bb0210","article-title":"Urinary exosomal microRNA profiling in intermediate-risk prostate cancer","volume":"11","author":"Kim","year":"2021","journal-title":"Sci. Rep."},{"issue":"19","key":"10.1016\/j.yexmp.2026.105085_bb0225","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11195637","article-title":"Drivers of radioresistance in prostate cancer","volume":"11","author":"King","year":"2022","journal-title":"J. Clin. Med."},{"issue":"10","key":"10.1016\/j.yexmp.2026.105085_bb0235","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-024-07133-3","article-title":"Loss of miR-200c-3p promotes resistance to radiation therapy via the DNA repair pathway in prostate cancer","volume":"15","author":"Labb\u00e9","year":"2024","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.yexmp.2026.105085_bb0230","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-020-01186-6","article-title":"MicroRNAs identified in prostate cancer: correlative studies on response to ionizing radiation","volume":"19","author":"Labb\u00e9","year":"2020","journal-title":"Mol. Cancer"},{"issue":"02","key":"10.1016\/j.yexmp.2026.105085_bb0240","doi-asserted-by":"crossref","first-page":"05","DOI":"10.18535\/jmscr\/v12i02.02","article-title":"Evolution of radiotherapy - a brief review","volume":"12","author":"Lahkar","year":"2024","journal-title":"J. Med. Sci. Clin. Res."},{"issue":"3","key":"10.1016\/j.yexmp.2026.105085_bb0245","doi-asserted-by":"crossref","DOI":"10.3390\/biology11030435","article-title":"Long-term outcomes of dose-escalated hypofractionated radiotherapy in localized prostate cancer","volume":"11","author":"Lazo","year":"2022","journal-title":"Biology"},{"issue":"29","key":"10.1016\/j.yexmp.2026.105085_bb0250","doi-asserted-by":"crossref","first-page":"10428","DOI":"10.12998\/wjcc.v10.i29.10428","article-title":"Prostate only radiotherapy using external beam radiotherapy: a clinician's perspective","volume":"10","author":"Lee","year":"2022","journal-title":"World J. Clin. Cases"},{"issue":"4","key":"10.1016\/j.yexmp.2026.105085_bb0255","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.3892\/ol.2015.3551","article-title":"microRNA-32 induces radioresistance by targeting DAB2IP and regulating autophagy in prostate cancer cells","volume":"10","author":"Liao","year":"2015","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.yexmp.2026.105085_bb0260","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-71128-1","article-title":"MicroRNA-107 enhances radiosensitivity by suppressing granulin in PC-3 prostate cancer cells","volume":"10","author":"Lo","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.yexmp.2026.105085_bb0265","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1200\/JCO.2020.38.6_suppl.328","article-title":"Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): efficacy, survival, and late toxicity outcomes","volume":"38","author":"Loblaw","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.yexmp.2026.105085_bb0270","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-019-0965-7","article-title":"Extracellular vesicles-mediated intercellular communication: roles in the tumor microenvironment and anti-cancer drug resistance","volume":"18","author":"Maacha","year":"2019","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.yexmp.2026.105085_bb0275","doi-asserted-by":"crossref","DOI":"10.1186\/s13148-021-01111-8","article-title":"Epigenetic mechanisms underlying prostate cancer radioresistance","volume":"13","author":"Macedo-Silva","year":"2021","journal-title":"Clin. Epigenetics"},{"issue":"21","key":"10.1016\/j.yexmp.2026.105085_bb0280","doi-asserted-by":"crossref","DOI":"10.7150\/jca.48216","article-title":"MicroRNA-29b-3p enhances radiosensitivity through modulating WISP1-mediated mitochondrial apoptosis in prostate cancer cells","volume":"11","author":"Mao","year":"2020","journal-title":"J. Cancer"},{"issue":"10","key":"10.1016\/j.yexmp.2026.105085_bb0285","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12136","article-title":"Androgens alter the heterogeneity of small extracellular vesicles and the small RNA cargo in prostate cancer","volume":"10","author":"Martens-Uzunova","year":"2021","journal-title":"J. Extracell. Vesicles"},{"issue":"19","key":"10.1016\/j.yexmp.2026.105085_bb0290","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914956","article-title":"New facets of DNA double strand break repair: radiation dose as key determinant of HR versus c-NHEJ engagement","volume":"24","author":"Mladenov","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"13","key":"10.1016\/j.yexmp.2026.105085_bb0295","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.7150\/thno.19934","article-title":"Targeting microRNAs in prostate cancer radiotherapy","volume":"7","author":"Ni","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.yexmp.2026.105085_bb0300","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00869","article-title":"Exosomes in cancer radioresistance","volume":"9","author":"Ni","year":"2019","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.yexmp.2026.105085_bb0305","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/jrr\/rraa064","article-title":"Reporting of methodologies used for clonogenic assays to determine radiosensitivity","volume":"61","author":"Oike","year":"2020","journal-title":"J. Radiat. Res."},{"issue":"11","key":"10.1016\/j.yexmp.2026.105085_bb0310","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1158\/2159-8290.CD-13-0172","article-title":"Androgen receptor signaling regulates DNA repair in prostate cancers","volume":"3","author":"Polkinghorn","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.yexmp.2026.105085_bb0315","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.canlet.2021.04.019","article-title":"Improving the therapeutic ratio of radiotherapy against radioresistant cancers: leveraging on novel artificial intelligence-based approaches for drug combination discovery","volume":"511","author":"Poon","year":"2021","journal-title":"Cancer Lett."},{"issue":"8","key":"10.1016\/j.yexmp.2026.105085_bb0320","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0330501","article-title":"Exosome-mediated modulation of radioresistance: the radiation-induced bystander effect in prostate cancer cells","volume":"20","author":"Pszcz\u00f3\u0142kowska-K\u0119pa","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.yexmp.2026.105085_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102736","article-title":"Radiation-induced extracellular vesicle (EV) release of miR-603 promotes IGF1-mediated stem cell state in glioblastomas","volume":"55","author":"Ramakrishnan","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.yexmp.2026.105085_bb0330","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.canlet.2019.12.025","article-title":"MiR-191 promotes radiation resistance of prostate cancer through interaction with RXRA","volume":"473","author":"Ray","year":"2020","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.yexmp.2026.105085_bb0335","first-page":"355","article-title":"Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer","volume":"4","author":"Recine","year":"2015","journal-title":"Transl. Androl. Urol."},{"issue":"3","key":"10.1016\/j.yexmp.2026.105085_bb0340","doi-asserted-by":"crossref","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","article-title":"NCCN guidelines\u00ae insights: Prostate cancer, version 3.2024","volume":"22","author":"Schaeffer","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"3","key":"10.1016\/j.yexmp.2026.105085_bb0345","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.eururo.2024.11.013","article-title":"Recent patterns and trends in global prostate cancer incidence and mortality: an update","volume":"87","author":"Schafer","year":"2025","journal-title":"Eur. Urol."},{"issue":"6","key":"10.1016\/j.yexmp.2026.105085_bb0350","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11060862","article-title":"Cancer stem cells and radioresistance: DNA repair and beyond","volume":"11","author":"Schulz","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.yexmp.2026.105085_bb0355","doi-asserted-by":"crossref","unstructured":"Sekhar, K. R., & Freeman, M. L. Nrf2 promotes survival following exposure to ionizing radiation. Free Radic. Biol. Med. 88:268\u201374. doi:https:\/\/doi.org\/10.1016\/j.freeradbiomed.2015.04.035.","DOI":"10.1016\/j.freeradbiomed.2015.04.035"},{"issue":"11","key":"10.1016\/j.yexmp.2026.105085_bb0360","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1038\/s12276-020-0431-z","article-title":"Cancer-associated fibroblast-secreted exosomal miR-423-5p promotes chemotherapy resistance in prostate cancer by targeting GREM2 through the TGF-\u03b2 signaling pathway","volume":"52","author":"Shan","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.yexmp.2026.105085_bb0365","doi-asserted-by":"crossref","unstructured":"Smolarz, M., Skoczylas, \u0141., Gawin, M., Krzy\u017cowska, M., Pietrowska, M., & Wid\u0142ak, P. Radiation-induced bystander effect mediated by exosomes involves the replication stress in recipient cells. Int. J. Mol. Sci. 23(8):4169. doi:https:\/\/doi.org\/10.3390\/ijms23084169.","DOI":"10.3390\/ijms23084169"},{"key":"10.1016\/j.yexmp.2026.105085_bb0370","article-title":"The influence of miRNAs on radiotherapy treatment in prostate cancer \u2013 a systematic review","volume":"11-2021","author":"Soares","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.yexmp.2026.105085_bb0375","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/454837","article-title":"The emerging role of extracellular vesicle-mediated drug resistance in cancers: implications in advanced prostate cancer","author":"Soekmadji","year":"2015","journal-title":"Biomed. Res. Int."},{"issue":"Suppl. 6","key":"10.1016\/j.yexmp.2026.105085_bb0380","article-title":"Androgen deprivation therapy and radiation therapy for prostate cancer: the mechanism underlying therapeutic synergy","volume":"7","author":"Spina","year":"2018","journal-title":"Transl. Cancer Res."},{"issue":"7","key":"10.1016\/j.yexmp.2026.105085_bb0385","doi-asserted-by":"crossref","first-page":"323.e17","DOI":"10.1016\/j.urolonc.2023.04.006","article-title":"Use of expectant management based on prostate cancer risk and health status: how far are we from a risk-adapted approach?","volume":"41","author":"Spratte","year":"2023","journal-title":"Urol. Oncol."},{"issue":"5","key":"10.1016\/j.yexmp.2026.105085_bb0390","doi-asserted-by":"crossref","first-page":"3646","DOI":"10.1097\/JS9.0000000000002334","article-title":"The lncRNAs PART1 and ADAMTS9-AS2 act in an antithetic manner on AR signaling and induction of cellular senescence in prostate cancer cells","volume":"111","author":"Taheri","year":"2025","journal-title":"Int. J. Surg."},{"issue":"4","key":"10.1016\/j.yexmp.2026.105085_bb0395","first-page":"318","article-title":"Alterations in TGF\u03b2 signaling during prostate cancer progression","volume":"9","author":"Thompson-Elliott","year":"2021","journal-title":"Am. J. Clin. Exp. Urol."},{"issue":"8","key":"10.1016\/j.yexmp.2026.105085_bb0400","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s10439-023-03215-z","article-title":"Human cancer cell radiation response investigated through topological analysis of 2D cell networks","volume":"51","author":"Tirinato","year":"2023","journal-title":"Ann. Biomed. Eng."},{"issue":"6","key":"10.1016\/j.yexmp.2026.105085_bb0405","doi-asserted-by":"crossref","first-page":"772","DOI":"10.2174\/156652412800792589","article-title":"Tissue biomarkers for prostate cancer radiation therapy","volume":"12","author":"Tran","year":"2012","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.yexmp.2026.105085_bb0410","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/iju.15043","article-title":"MiRNAs in prostate cancer: intercellular and extracellular communications","volume":"29","author":"Urabe","year":"2022","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.yexmp.2026.105085_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118871","article-title":"Exosomes derived from miR-34a-overexpressing mesenchymal stem cells inhibit in vitro tumor growth: a new approach for drug delivery","volume":"266","author":"Vakhshiteh","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.yexmp.2026.105085_bb0420","article-title":"DNA double strand break repair pathways in response to different types of ionizing radiation","volume":"12-2021","author":"van de Kamp","year":"2021","journal-title":"Front. Genet."},{"issue":"33","key":"10.1016\/j.yexmp.2026.105085_bb0430","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1038\/onc.2015.446","article-title":"STAT3 selectively interacts with Smad3 to antagonize TGF-\u03b2","volume":"35","author":"Wang","year":"2016","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.yexmp.2026.105085_bb0435","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11010112","article-title":"Hypoxic radioresistance: can ROS be the key to overcome it?","volume":"11","author":"Wang","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.yexmp.2026.105085_bb0425","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.12659\/MSM.896832","article-title":"Hypoxia-responsive Mir-301a and Mir-301b promote radioresistance of prostate cancer cells via downregulating NDRG2","volume":"22","author":"Wang","year":"2016","journal-title":"Med. Sci. Monit."},{"issue":"7","key":"10.1016\/j.yexmp.2026.105085_bb0440","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12342","article-title":"Stromal cell-derived small extracellular vesicles enhance radioresistance of prostate cancer cells via interleukin-8-induced autophagy","volume":"12","author":"Wang","year":"2023","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.yexmp.2026.105085_bb0445","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.2147\/OTT.S158206","article-title":"The role of HIF-1\u03b1 in chemo\u2212\/radioresistant tumors","volume":"11","author":"Xia","year":"2018","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.yexmp.2026.105085_bb0450","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.omtn.2018.08.009","article-title":"MiR-17-3p downregulates mitochondrial antioxidant enzymes and enhances the radiosensitivity of prostate cancer cells","volume":"13","author":"Xu","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.yexmp.2026.105085_bb0455","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202201609","article-title":"Extracellular vesicles in cancer drug resistance: roles, mechanisms, and implications","volume":"9","author":"Yang","year":"2022","journal-title":"Adv. Sci."},{"issue":"14","key":"10.1016\/j.yexmp.2026.105085_bb0460","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26146853","article-title":"The role of PI3K\/AKT\/mTOR signaling in tumor radioresistance and advances in inhibitor research","volume":"26","author":"Zhan","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yexmp.2026.105085_bb0465","article-title":"The roles of HIF-1\u03b1 in radiosensitivity and radiation-induced bystander effects under hypoxia","volume":"9-2021","author":"Zhang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.yexmp.2026.105085_bb0475","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41392-023-01382-y","article-title":"Engineered exosomes from different sources for cancer-targeted therapy","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.yexmp.2026.105085_bb0470","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1093\/jrr\/rrab117","article-title":"STAT3 as a target for sensitizing prostate cancer cells to irradiation","volume":"63","author":"Zhang","year":"2022","journal-title":"J. Radiat. Res."},{"key":"10.1016\/j.yexmp.2026.105085_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119798","article-title":"MiR-223-3p targets FOXO3a to inhibit radiosensitivity in prostate cancer by activating glycolysis","volume":"282","author":"Zhou","year":"2021","journal-title":"Life Sci."}],"container-title":["Experimental and Molecular Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448002600064X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448002600064X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T14:23:21Z","timestamp":1793024601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001448002600064X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":96,"alternative-id":["S001448002600064X"],"URL":"https:\/\/doi.org\/10.1016\/j.yexmp.2026.105085","relation":{},"ISSN":["0014-4800"],"issn-type":[{"value":"0014-4800","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MicroRNAs in prostate cancer radioresistance: mechanisms, target-based network analysis and translational opportunities","name":"articletitle","label":"Article Title"},{"value":"Experimental and Molecular Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexmp.2026.105085","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"105085"}}